MEDIAN TECHNOLOGIES (EPA:ALMDT)

PRESS RELEASE

published on 02/11/2026 at 17:45, 7 months 12 days ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Disclosure of total voting rights and shares as of Jan 31, 2026 by Median Technologies. Cutting-edge AI for cancer diagnoses and treatments. Listed on Euronext Growth market

Voting Rights Shares AI Median Technologies Cancer Diagnoses
PRESS RELEASE

published on 02/11/2026 at 17:45, 7 months 12 days ago

Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital de Median Technologies au 31 janvier 2026

Capital Déclaration Droits De Vote Median Technologies Technologies De L'IA
BRIEF

published on 02/09/2026 at 07:05, 7 months 14 days ago

Autorisation de la FDA accordée au dispositif de dépistage du cancer du poumon basé sur l'IA de Median Technologies

Technologie IA Autorisation De La FDA Dépistage Du Cancer Du Poumon Eyonis® LCS Voie De Remboursement
BRIEF

published on 02/09/2026 at 07:05, 7 months 14 days ago

FDA Clearance Granted for Median Technologies' AI-based Lung Cancer Device

FDA Clearance AI Technology Lung Cancer Screening Eyonis® LCS Reimbursement Pathway
BRIEF

published on 02/09/2026 at 07:05, 7 months 14 days ago

Median Technologies reçoit l'autorisation 510(k) de la FDA pour eyonis® LCS

FDA Technologie IA Median Technologies Eyonis® LCS Dépistage Cancer Poumon
BRIEF

published on 02/09/2026 at 07:05, 7 months 14 days ago

Median Technologies receives FDA 510(k) clearance for eyonis® LCS

FDA AI Technology Median Technologies Lung Cancer Screening Eyonis® LCS
PRESS RELEASE

published on 02/09/2026 at 07:00, 7 months 14 days ago

Inside Information / Operations of the issuer (acquisitions, sales...)
Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening. The device aims to redefine lung cancer screening with high accuracy and potential to save lives

FDA Clearance AI Technology Median Technologies Eyonis LCS Lung Cancer Screening
PRESS RELEASE

published on 02/09/2026 at 07:00, 7 months 14 days ago

Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Median Technologies obtient l'autorisation 510(k) de la FDA pour eyonis® LCS, logiciel IA dépistage cancer poumon. Nouveau paradigme dépistage. Déploiement à grande échelle en cours

Dépistage Median Technologies Cancer Du Poumon Autorisation 510(k) Eyonis® LCS
BRIEF

published on 01/14/2026 at 17:50, 8 months 9 days ago

Median Technologies : Calendrier Financier et Participation à des Conférences en 2026

Calendrier Financier Résultats Annuels Conférences Investisseurs Median Technologies Imagerie Médicale IA
BRIEF

published on 01/14/2026 at 17:50, 8 months 9 days ago

Median Technologies: Financial Calendar and Conference Participation in 2026

Investor Conferences Financial Calendar Annual Results Median Technologies AI-powered Medical Imaging

Published on 09/23/2026 at 22:00, 4 hours 14 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 49 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 10 hours 32 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 11 hours 43 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 11 hours 44 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

Published on 09/23/2026 at 23:00, 3 hours 14 minutes ago

Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS
Published on 09/23/2026 at 23:00, 3 hours 14 minutes ago

Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 6 hours 22 minutes ago

LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:51, 6 hours 22 minutes ago

LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 19:30, 6 hours 44 minutes ago

EUROPLASMA: Valdunes Industries et Saarstahl Ascoval s’associent pour développer une nouvelle génération de « roues vertes »

View all EQS

Published on 09/23/2026 at 19:46, 6 hours 27 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 6 hours 27 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 6 hours 59 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 6 hours 59 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 8 hours 14 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News